GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » EV-to-EBIT

MariMed (MariMed) EV-to-EBIT : 63.89 (As of Apr. 28, 2024)


View and export this data going back to 2012. Start your Free Trial

What is MariMed EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MariMed's Enterprise Value is $165.4 Mil. MariMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $2.6 Mil. Therefore, MariMed's EV-to-EBIT for today is 63.89.

The historical rank and industry rank for MariMed's EV-to-EBIT or its related term are showing as below:

MRMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -504.78   Med: -0.96   Max: 158.6
Current: 63.89

During the past 13 years, the highest EV-to-EBIT of MariMed was 158.60. The lowest was -504.78. And the median was -0.96.

MRMD's EV-to-EBIT is ranked worse than
91.02% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs MRMD: 63.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MariMed's Enterprise Value for the quarter that ended in Dec. 2023 was $166.8 Mil. MariMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $2.6 Mil. MariMed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.55%.


MariMed EV-to-EBIT Historical Data

The historical data trend for MariMed's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed EV-to-EBIT Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.63 12.96 10.77 6.89 64.44

MariMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.89 10.30 11.93 15.37 64.44

Competitive Comparison of MariMed's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MariMed's EV-to-EBIT falls into.



MariMed EV-to-EBIT Calculation

MariMed's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=165.402/2.589
=63.89

MariMed's current Enterprise Value is $165.4 Mil.
MariMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MariMed  (OTCPK:MRMD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MariMed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=2.589/166.8266248
=1.55 %

MariMed's Enterprise Value for the quarter that ended in Dec. 2023 was $166.8 Mil.
MariMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MariMed EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of MariMed's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (MariMed) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R Levine 10 percent owner C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw officer: Chief Operating Officer C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker director C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare officer: Chief Financial Officer C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d. director C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin director 11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman director 310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman director 145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc. director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY 11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan officer: CFO, VICE PRESIDENT 11 ROYAL RD, BROOKLINE MA 02445